Ravi Uppaluri, MDPhD
@DrUppaluri
Director, Head and Neck Surgical Oncology, Chief of Otolaryngology, Brigham and Women’s and Dana-Farber Cancer Institute
Interim results from KEYNOTE-689 (NEJM): Perioperative pembrolizumab + standard care improved 3-yr EFS in locally advanced HNSCC (CPS ≥10: 59.8% vs 45.9%). Led by @DrUppaluri. Details: ascopost.com/news/june-2025… #KEYNOTE689 #HNSCC #Oncology
Tomorrow is the #SITC Summit on the Future of Neoadjuvant Clinical Trial Design, which will discuss the recent advances in clinical trials for resectable tumors. The Neoadjuvant Clinical Trial Design Working Group is chaired by Patrick Forde, MD. Register: sitcancer.org/neoadjuvant-vs
FDA approves pembrolizumab for resectable, locally advanced HNSCC based on KEYNOTE‑689. Led by Dr. Ravindra Uppaluri @DrUppaluri, the study showed a 30% drop in recurrence risk. Full details from The ASCO Post: ascopost.com/news/june-2025… #HNSCC #Oncology
Exciting news in the head and neck cancer space. KEYNOTE-689 resulted in the first FDA approval for patients with HNSCC in 6 years. Congrats to @DrUppaluri, Doug Adkins, and the rest of the team worldwide. fda.gov/drugs/resource…
The results of the KEYNOTE-689 trial that served as the basis for this approval were recently presented by @DrUppaluri of @HarvardMed and @BrighamWomens at #AACR25. Read more about the trial results on the #AACRBlog: aacr.org/blog/2025/04/3…
#BREAKING The @FDA has approved pembrolizumab as the first new standard-of-care treatment for patients with resectable locally advanced #HeadandNeck cancer in 20+ years. Approval based on the pivotal KEYNOTE-689 trial led by @DrUppaluri of the @DanaFarber Brigham Cancer Center.…
Today’s #FDA approval marks a significant step forward for certain patients with head and neck squamous cell carcinoma. Learn more here: merck.us/4e7cEYS
Thanks @DrGopalIyer !!! Has been quite a journey from an idea we had in the early 2010s to change standard of care (with DAdkins at WashU as a partner on all this work)- exciting news for our patients.
Not everyday someone gets to change practice.. this is why we all do what we do….this is the dream!!!!
The standard of care has finally changed for patients with resectable head and neck #cancer!! Congratulations @DrUppaluri and all the #KN-689 investigators. fda.gov/drugs/resource…
Boom!💥 @FDA approves neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck squamous cell carcinoma, ushering in a new standard of care for the first time in decades. fda.gov/drugs/resource…
If you are attending @AHNSinfo, please join Dr. Stephen Lai & me this evening (Wed) in Celestin E at 6:15pm for updates on @NRGonc HN006 AND to hear PRACTICE CHANGING data from Keynote 689, the Ph3 trial of perioperative pembrolizumab recently presented @AACR by @DrUppaluri
“It’s really exciting. It’s a new frontier for our patients.” @DrUppaluri of @DanaFarber discussed data from KEYNOTE-689 trial that showed @KEYTRUDA significantly extended EFS for patients with advanced HNSCC. @AACR @BrighamWomens @harvardmed bit.ly/3YPEsdE
As #HeadAndNeckCancer Month comes to a close, we reflect on the exciting phase 3 clinical trial results shared by @DanaFarber's @DrUppaluri in @AJMC_Journal showing significantly extended event-free survival for patients with locally advanced head and neck cancer. @DrHaddadRobert…
Adding perioperative pembrolizumab to standard of care is “a new frontier” for head and neck cancer, @DanaFarber's @DrUppaluri tells @GoHealio. Read more: bit.ly/435ercJ
#KEYNOTE689: Adding #Pembrolizumab before and after surgery significantly improves EFS in resectable LA-HNSCC. A potential new standard of care after 20+ years of stagnation. bit.ly/4cVzF0j #LARVOL #AACR25 #HNSCC #CancerResearch @DrUppaluri
Keytruda Plus SOC: New Standard for Advanced Head & Neck Cancer | #AACR25 @DrUppaluri @DanaFarber hubs.li/Q03k6bMg0